Novo Nordisk A/S Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: 26-JulOwnership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Novo Nordisk's governance structure is among the most unusual in global pharmaceutical history. A charitable foundation established in 1926 controls a company with a market capitalisation that at its peak exceeded $550 billion, making Novo Nordisk the most valuable company in European history. The Novo Nordisk Foundation's mandate, to advance healthcare and the sustainability of society, is implemented primarily through its ownership of Novo Nordisk. The Foundation does not distribute dividends to charitable causes in the conventional sense; it reinvests returns from Novo Nordisk into funding new science through grants and through Novo Holdings' investment activities. This structure gives Novo Nordisk a permanent anchor shareholder with an explicit mission alignment with the pharmaceutical business. The governance intervention that produced the August 2025 CEO change is the most consequential board action in Novo Nordisk's modern history. Lars Fruergaard Jørgensen had been a celebrated CEO who guided the company through the GLP-1 revolution; his departure after lower-than-expected US Wegovy growth reflects the Foundation's view that the competitive response to Eli Lilly's tirzepatide required different leadership capabilities. The full board reconstitution at the October 2025 Extraordinary General Meeting, during which most existing board members were replaced, is even more dramatic: it represents the Foundation imposing a governance reset at a company it has controlled for over 100 years.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Novo Holdings at 28% and 76% of votes is the governance reality at Novo Nordisk. All other shareholders, including Vanguard at 3.8%, BlackRock at 2.9%, and State Street at 1.7%, are passive. Their collective economic stake is meaningful but their governance influence is zero relative to the Foundation's voting control. The public ADR shareholders in the US hold Class B shares with lower voting rights, meaning that even a 100% coalition of all non-Foundation shareholders could not overcome the Foundation's 76% voting control. This creates an interesting investment dynamic: investors who buy Novo Nordisk ADRs are investing in a business they cannot govern. They are betting entirely on the Foundation's stewardship quality and the management team's commercial execution. When that execution was strong, as during the 2021 to 2024 GLP-1 boom, the ADR returned over 500% and made Novo Nordisk the most valuable European company by market cap. When the competitive response to tirzepatide proved slower than expected and US Wegovy market share began to erode in 2025, the same investor base had no governance mechanism to force a faster strategic change.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Ozempic (semaglutide) | Brand | GLP-1 receptor agonist injectable approved for type 2 diabetes; the world's best-selling drug in 2024 by revenue; facing growing competition from Eli Lilly's tirzepatide in the diabetes market as physicians switch to the dual GIP-GLP-1 mechanism |
| Wegovy (semaglutide) | Brand | Same semaglutide molecule as Ozempic dosed higher and branded for weight loss and obesity treatment; the fastest-growing drug by absolute revenue addition in pharmaceutical history; 59.6% global branded obesity volume market share |
| Victoza (liraglutide) | Brand | Legacy GLP-1 receptor agonist for type 2 diabetes; declining as prescribers switch to the more effective semaglutide products |
| Tresiba (insulin degludec) | Brand | Ultra-long-acting basal insulin for type 1 and type 2 diabetes; part of Novo Nordisk's comprehensive insulin portfolio built over 100 years |
| Norditropin | Brand | Growth hormone for growth hormone deficiency in children and adults; part of the Rare Disease portfolio contributing to segment revenue alongside haemophilia products |
| Rybelsus (oral semaglutide) | Brand | First oral GLP-1 receptor agonist approved for type 2 diabetes; competes with Eli Lilly's Foundayo oral GLP-1 approved in 2026 |
Portfolio Analysis
Novo Nordisk's brand architecture for the GLP-1 era has two levels. At the product level, Ozempic and Wegovy are the same molecule semaglutide differentiated by dose and indication. Ozempic is approved for type 2 diabetes. Wegovy is approved for obesity at a higher weekly dose. The commercial separation was deliberate and strategic: pricing obesity indications higher than diabetes indications reflects different payer dynamics and different patient willingness-to-pay. The challenge is that clinical reality does not respect this commercial separation; physicians prescribe Ozempic for weight loss in patients who do not have type 2 diabetes, creating a grey market that has complicated Novo Nordisk's supply management. Rybelsus, the oral semaglutide for type 2 diabetes, was commercially interesting before Eli Lilly's Foundayo approval in 2026, which offers oral GLP-1 without the food and water restrictions that limited Rybelsus's adoption. Rybelsus's competitive positioning weakened significantly with Foundayo's approval. The Novo Nordisk corporate brand carries a specific Danish identity: a company founded by scientists for scientific purposes that has operated in diabetes for 100 years. That brand heritage gives Novo Nordisk credibility in the GLP-1 category that newer entrants cannot claim.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Novo Nordisk ★ | 59.6% branded obesity volume share | $41.2B | Danish pharma controlling global GLP-1 obesity market; facing tirzepatide competition from Eli Lilly |
| Eli Lilly | N/A | $65.2B | Primary GLP-1 competitor; Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) outperforming semaglutide on weight loss efficacy in clinical trials |
| Roche | N/A | N/A | Developing CT-388 dual receptor agonist for obesity; potential future competitor but years from commercial scale |
| AstraZeneca | N/A | N/A | Competing in GLP-1 adjacent cardiovascular and metabolic disease with Farxiga |
| Pfizer | N/A | $62.6B | Developing oral obesity treatments including danuglipron; competitive in the medium-term pipeline |
Competitive Analysis
Novo Nordisk's competitive position in the GLP-1 obesity market is the most consequential pharmaceutical market share battle of the decade. Novo Nordisk holds 59.6% of branded obesity treatment volume globally but has been losing share to Eli Lilly's tirzepatide, which produces greater weight loss than semaglutide in head-to-head comparisons. The clinical superiority of tirzepatide's dual GIP-GLP-1 mechanism over semaglutide's pure GLP-1 mechanism is now well established, which creates a long-term competitive challenge that Novo Nordisk cannot address by improving the existing semaglutide drug. The company's response includes next-generation molecules: CagriSema, a combination of semaglutide and a second agent called cagrilintide, showed superior weight loss to semaglutide alone in early trials but missed its primary endpoint in a key late-stage trial in early 2025. Amycretin, an oral combination of semaglutide and amylin, is in early clinical development. Novo Nordisk's competitive position in 2030 will depend on whether these next-generation molecules can reclaim the efficacy leadership that tirzepatide currently holds.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Catalent (three fill-finish sites) | $16.5B | 2024 | Acquired three Catalent pharmaceutical manufacturing sites from Blackstone as part of Blackstone's acquisition of Catalent; gave Novo Nordisk critical fill-finish manufacturing capacity to meet Wegovy and Ozempic demand |
| Forma Therapeutics | $1.1B | 2022 | Rare blood disorder company developing treatments for sickle cell disease |
| Dicerna Pharmaceuticals | $3.3B | 2021 | RNA interference therapeutics company; technology potentially applicable to metabolic disease targets |
| Cardior Pharmaceuticals | Undisclosed | 2024 | RNA therapeutic company for heart failure |
Acquisitions Analysis
Novo Nordisk's most consequential acquisition was not a company but a manufacturing asset: the purchase of three Catalent fill-finish manufacturing sites from Blackstone for $16.5 billion in 2024. This transaction was driven by a production constraint that was genuinely limiting Wegovy supply: the demand for semaglutide injectors outpaced Novo Nordisk's manufacturing capacity beginning in 2022, resulting in supply shortages that constrained prescription volume and allowed Eli Lilly's tirzepatide to gain market share in a period when Novo Nordisk could not fully supply the existing demand. Paying $16.5 billion for manufacturing capacity rather than drug development intellectual property is unusual in pharmaceutical M&A but reflects the commercial reality that in the GLP-1 category, the bottleneck was manufacturing rather than science. The Dicerna acquisition for $3.3 billion in 2021 brought RNA interference technology that Novo Nordisk believes can be applied to metabolic disease targets beyond the GLP-1 mechanism. RNA interference therapeutics, which reduce the expression of specific disease-causing genes, represent a potential next generation of treatments that could extend Novo Nordisk's pharmaceutical leadership beyond the semaglutide era.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Novo Nordisk's 1989 merger of Novo and Nordisk, two Danish pharmaceutical companies that had both been producing insulin since 1923, created the single entity that became the world's most valuable pharmaceutical company by market capitalisation in 2024. The two original companies had been competitors for decades in insulin, which is the therapeutic category that defines Novo Nordisk's origin and foundational scientific expertise. Their merger created a company large enough to fund the research programmes that ultimately produced the GLP-1 agonist class. Without the scale that the 1989 merger created, Novo Nordisk could not have funded the 20 years of GLP-1 research that produced liraglutide (Victoza) in 2012 and semaglutide (Ozempic in 2017, Wegovy in 2021). The 2024 acquisition of Catalent manufacturing assets for $16.5 billion is the most significant M&A event since the 1989 Novo-Nordisk merger, and like that merger, it was motivated by industrial logic rather than financial engineering.
Ownership History
Ownership History Analysis
Novo Nordisk traces its origin to 1923 when two separate Danish scientists, August Krogh and Marie Krogh, brought the insulin discovery from Canada to Denmark. Both Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium began producing insulin in 1923, and both were supported by the Danish pharmaceutical establishment. The Novo Nordisk Foundation, which today controls the company, was established in 1926 to hold shares in Novo Terapeutisk and ensure the company's profits would be reinvested in science rather than distributed to shareholders. This 1926 governance structure, established 99 years ago, is still the structure that controls Novo Nordisk today. Lars Fruergaard Jorgensen's eight-year CEO tenure from 2017 to 2025 encompassed the most commercially extraordinary period in Novo Nordisk's history: the rise of semaglutide from a diabetes drug to the defining treatment of the global obesity epidemic. His departure in August 2025, as tirzepatide competition eroded the leadership position he had built, represents the inevitable governance consequence of missing competitive expectations at a company where the Foundation exercises active oversight of management quality.
Ownership Explained
Novo Nordisk A/S is a publicly traded Danish pharmaceutical company in which Novo Holdings AS, the investment vehicle of the Novo Nordisk Foundation, holds 28% of shares and 76% of voting rights through a Class A and Class B dual-share structure. The Novo Nordisk Foundation is a Danish charitable foundation whose mandate is to advance science and improve human health. It has controlled Novo Nordisk for over 100 years. Maziar Mike Doustdar became CEO on August 7, 2025, succeeding Lars Fruergaard Jørgensen who stepped down after eight years leading the company through the GLP-1 revolution. FY2025 net sales were DKK 309.064 billion, equivalent to $41.2 billion, up 10% at constant exchange rates. Novo Nordisk initiated a company-wide transformation in September 2025 that reduced headcount by 9,000 employees.
The Novo Nordisk Foundation's control of 76% of voting rights through Novo Holdings gives the foundation permanent governance authority over Novo Nordisk that no public market event can override. The board cannot be replaced by hostile shareholders, and no acquisition can succeed without the Foundation's consent. This structure allowed Novo Nordisk to invest in GLP-1 research for decades before the commercial potential of the obesity indication became clear. The Foundation's mandate to advance healthcare aligned with the long-duration research investment that produced semaglutide. The governance challenge in 2025 was the reverse: the Foundation's long-duration orientation did not accelerate the strategic response to Eli Lilly's tirzepatide competition as quickly as conventional board accountability might have. The CEO change, board reconstitution, and 9,000-person reduction in September 2025 suggest the Foundation ultimately recognised that the pace of competitive response required a leadership change.